ACVR1B and cancer: Knockdown or pharmacological inhibition of the Nodal/Activin receptor Alk4/7 in cancer stem cells virtually abrogated their self-renewal capacity and in vivo tumorigenicity and reversed the resistance of orthotopically engrafted cancer stem cells to gemcitabine.